Corbus schedules November 11 results: Corbus Pharmaceuticals stock sits 76.80 percent below its high

Published on 10/20/2026 at 18:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 GAAP earnings per share were USD -1.81 on June 30, 2026. Corbus Pharmaceuticals stock costs EUR 4.11 on October 20, 2026 in after hours.

Reporting date and loss

Corbus Pharmaceuticals has a November 11, 2026 reporting date for third-quarter results.
GAAP earnings per share were USD -1.81 for the quarter ended June 30, 2026.
Corbus Pharmaceuticals stock costs EUR 4.11 at Lang & Schwarz on October 20, 2026 at 6:33 p.m. CEST.

CRBP, US21833P3010, Illustration mit AI erstellt.

Corbus Pharmaceuticals has a scheduled November 11, 2026 report for third-quarter results, giving investors a defined date for the next review of its clinical-stage pipeline. MarketBeat lists the announcement for before the market opens and a conference call for November 6, 2026. At Lang & Schwarz, the stock was EUR 4.11 on October 20, 2026 at 6:33 p.m. CEST.

November date sets the next test

The November report will be judged against a difficult recent earnings profile. For the quarter ended June 30, 2026, Corbus posted GAAP earnings per share of USD -1.81 and revenue of USD 0, while the consensus earnings estimate was USD -1.30, according to Earnings Today. The same period produced a net loss of USD 35.04 million.

Stock remains near its yearly low

Corbus traded at USD 4.64 on Nasdaq at 12:38 p.m. ET on October 20, 2026, according to the market quote, with a market capitalization of USD 89.7 million. Its 52-week range was USD 4.22 to USD 20.00, leaving the stock 76.80 percent below the high and 9.95 percent above the low. The Nasdaq listing and the CRBP ticker identify the primary U.S. market for the shares.

Losses shape the November comparison

MarketBeat puts the consensus estimate for the quarter ending September 30, 2026 at a GAAP loss of USD 1.2141 per share and revenue of USD 2.00 million. The prior-year comparison is a loss of USD 1.90 per share, so the November release will provide a numerical test of whether the expected loss narrows. Corbus' investor-relations page identifies Q2 2026 as the latest financial-results period and describes CRB-701, CRB-601 and CRB-913 as its main development programs.

What the date means for investors

The November 11 report is the next scheduled point for updated financial figures and clinical-program commentary. The immediate market frame combines a USD 89.7 million valuation with a USD 35.04 million quarterly loss, making the reported cash position, research spending and development updates important details in the release.

Price and reporting date

Corbus Pharmaceuticals stock was at EUR 4.11 at Lang & Schwarz on October 20, 2026 at 6:33 p.m. CEST. The euro quotation is an after-hours indication for German investors, while the primary listing remains Nasdaq in USD.

The further course of trading is shown by the continuously updated real-time quote of Corbus Pharmaceuticals stock.